JP2015514075A - 脳癌の治療 - Google Patents

脳癌の治療 Download PDF

Info

Publication number
JP2015514075A
JP2015514075A JP2015501952A JP2015501952A JP2015514075A JP 2015514075 A JP2015514075 A JP 2015514075A JP 2015501952 A JP2015501952 A JP 2015501952A JP 2015501952 A JP2015501952 A JP 2015501952A JP 2015514075 A JP2015514075 A JP 2015514075A
Authority
JP
Japan
Prior art keywords
triazolo
yloxy
amino
pyridin
methylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015501952A
Other languages
English (en)
Japanese (ja)
Inventor
パトリース エー． リー，
パトリース エー． リー，
シャノン エル． ウィンスキー，
シャノン エル． ウィンスキー，
ケビン コッホ，
ケビン コッホ，
Original Assignee
アレイ バイオファーマ、インコーポレイテッド
アレイ バイオファーマ、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48048296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015514075(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アレイ バイオファーマ、インコーポレイテッド, アレイ バイオファーマ、インコーポレイテッド filed Critical アレイ バイオファーマ、インコーポレイテッド
Publication of JP2015514075A publication Critical patent/JP2015514075A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2015501952A 2012-03-23 2013-03-25 脳癌の治療 Pending JP2015514075A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615082P 2012-03-23 2012-03-23
US61/615,082 2012-03-23
PCT/US2013/033751 WO2013142875A1 (en) 2012-03-23 2013-03-25 Treatment of brain cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017103957A Division JP2017141302A (ja) 2012-03-23 2017-05-25 脳癌の治療

Publications (1)

Publication Number Publication Date
JP2015514075A true JP2015514075A (ja) 2015-05-18

Family

ID=48048296

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015501952A Pending JP2015514075A (ja) 2012-03-23 2013-03-25 脳癌の治療
JP2017103957A Pending JP2017141302A (ja) 2012-03-23 2017-05-25 脳癌の治療
JP2019034250A Active JP6898960B2 (ja) 2012-03-23 2019-02-27 脳癌の治療
JP2021097676A Pending JP2021178820A (ja) 2012-03-23 2021-06-11 脳癌の治療
JP2022177278A Active JP7404485B2 (ja) 2012-03-23 2022-11-04 脳癌の治療
JP2023209972A Pending JP2024019526A (ja) 2012-03-23 2023-12-13 脳癌の治療

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017103957A Pending JP2017141302A (ja) 2012-03-23 2017-05-25 脳癌の治療
JP2019034250A Active JP6898960B2 (ja) 2012-03-23 2019-02-27 脳癌の治療
JP2021097676A Pending JP2021178820A (ja) 2012-03-23 2021-06-11 脳癌の治療
JP2022177278A Active JP7404485B2 (ja) 2012-03-23 2022-11-04 脳癌の治療
JP2023209972A Pending JP2024019526A (ja) 2012-03-23 2023-12-13 脳癌の治療

Country Status (30)

Country Link
US (3) US20150110780A1 (enExample)
EP (4) EP4252855A3 (enExample)
JP (6) JP2015514075A (enExample)
KR (3) KR102160462B1 (enExample)
CN (2) CN104203279B (enExample)
AU (4) AU2013234921A1 (enExample)
CA (1) CA2867723C (enExample)
CL (1) CL2014002497A1 (enExample)
CO (1) CO7071139A2 (enExample)
CY (2) CY1120204T1 (enExample)
DK (2) DK3400943T3 (enExample)
ES (2) ES2855142T3 (enExample)
HR (1) HRP20180659T1 (enExample)
HU (2) HUE053156T2 (enExample)
IL (3) IL234627B (enExample)
LT (1) LT2827900T (enExample)
MX (1) MX354024B (enExample)
MY (2) MY174883A (enExample)
NZ (4) NZ630843A (enExample)
PH (2) PH12021550360A1 (enExample)
PL (2) PL2827900T3 (enExample)
PT (2) PT3400943T (enExample)
RS (1) RS57140B1 (enExample)
RU (2) RU2672575C2 (enExample)
SG (1) SG11201405954YA (enExample)
SI (2) SI3400943T1 (enExample)
SM (1) SMT201800251T1 (enExample)
TR (1) TR201808450T4 (enExample)
UA (1) UA122044C2 (enExample)
WO (1) WO2013142875A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021520930A (ja) * 2018-04-09 2021-08-26 ノボキュア ゲーエムベーハー ＴＴＦｉｅｌｄｓ及びオーロラキナーゼ阻害剤による腫瘍の治療

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116875C2 (uk) 2011-10-14 2018-05-25 Еррей Біофарма Інк. Поліморфи arry-380 селективного інгібітору erbb2 і фармацевтичні композиції, що їх містять
AU2012322039C1 (en) 2011-10-14 2021-04-29 Array Biopharma Inc. Solid dispersions of a Erb2 (HER2) inhibitor
PL2827900T3 (pl) 2012-03-23 2018-08-31 Array Biopharma, Inc. Dyspersja bezpostaciowego ciała stałego do zastosowania w leczeniu nowotworu mózgu
CA3055957A1 (en) 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
AU2018258663B2 (en) 2017-04-28 2022-08-04 Seagen Inc. Treatment of HER2 positive cancers
JP2021512105A (ja) 2018-01-31 2021-05-13 デシフェラ・ファーマシューティカルズ，エルエルシー 消化管間質腫瘍の治療のための併用療法
JP7523351B2 (ja) 2018-01-31 2024-07-26 デシフェラ・ファーマシューティカルズ，エルエルシー 肥満細胞症の治療のための併用療法
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
CN111825604A (zh) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 一种图卡替尼及其中间产物的合成方法
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
NZ789199A (en) 2019-12-30 2025-07-25 Deciphera Pharmaceuticals Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
AU2020419197B2 (en) * 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515988A (ja) * 2005-11-15 2009-04-16 アレイ バイオファーマ、インコーポレイテッド 過剰増殖性疾患の処置のためのＥｒｂＢＩ型受容体チロシンキナーゼ阻害剤としてのＮ４−フェニルキナゾリン−４−アミン誘導体および関連化合物
JP2014528484A (ja) * 2011-10-14 2014-10-27 アレイ バイオファーマ、インコーポレイテッド 固体分散体
JP2014530243A (ja) * 2011-10-14 2014-11-17 アレイ バイオファーマ、インコーポレイテッド Ａｒｒｙ−３８０の多形体、選択的ｈｅｒｂ２阻害剤、およびそれらを含有する薬学的組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690163A5 (fr) * 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
RU2255765C2 (ru) * 2000-01-21 2005-07-10 Чилдренз Хоспитал Лос-Анджелес Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов
US20020137731A1 (en) 2000-05-30 2002-09-26 Gewirtz David A. Combination of radiation and vitamin D3 analogs for the treatment of cancer
EP1660090B1 (en) 2003-08-14 2012-11-21 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN1989112A (zh) * 2004-06-03 2007-06-27 史密丝克莱恩比彻姆（科克）有限公司 癌症治疗方法
US20100063074A1 (en) 2004-06-03 2010-03-11 Berger Mark S Cancer Treatment Method
JP5068270B2 (ja) 2006-01-31 2012-11-07 ノバルティス アーゲー 癌を処置するためのｉｌ−１７アンタゴニスト抗体
JP2010540460A (ja) * 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療
HUE025507T2 (en) * 2008-03-18 2016-02-29 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
PL2827900T3 (pl) 2012-03-23 2018-08-31 Array Biopharma, Inc. Dyspersja bezpostaciowego ciała stałego do zastosowania w leczeniu nowotworu mózgu

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515988A (ja) * 2005-11-15 2009-04-16 アレイ バイオファーマ、インコーポレイテッド 過剰増殖性疾患の処置のためのＥｒｂＢＩ型受容体チロシンキナーゼ阻害剤としてのＮ４−フェニルキナゾリン−４−アミン誘導体および関連化合物
JP2014528484A (ja) * 2011-10-14 2014-10-27 アレイ バイオファーマ、インコーポレイテッド 固体分散体
JP2014530243A (ja) * 2011-10-14 2014-11-17 アレイ バイオファーマ、インコーポレイテッド Ａｒｒｙ−３８０の多形体、選択的ｈｅｒｂ２阻害剤、およびそれらを含有する薬学的組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ＫＯＣＨ，ＫＥＶＩＮ．ＡＲＲＹ−３８０：Ａ ＳＥＬＥＣＴＩＶＥ，ＯＲＡＬ ＨＥＲ２ ＩＮＨＩＢＩＴＯ, JPN6016045135, ISSN: 0003446514 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021520930A (ja) * 2018-04-09 2021-08-26 ノボキュア ゲーエムベーハー ＴＴＦｉｅｌｄｓ及びオーロラキナーゼ阻害剤による腫瘍の治療
JP7139448B2 (ja) 2018-04-09 2022-09-20 ノボキュア ゲーエムベーハー ＴＴＦｉｅｌｄｓ及びオーロラキナーゼ阻害剤による腫瘍の治療

Also Published As

Publication number Publication date
KR102317166B1 (ko) 2021-10-26
JP2022190126A (ja) 2022-12-22
EP2827900A1 (en) 2015-01-28
US20190255051A1 (en) 2019-08-22
IL234627B (en) 2018-10-31
PL2827900T3 (pl) 2018-08-31
EP4252855A3 (en) 2023-11-15
JP2021178820A (ja) 2021-11-18
MX354024B (es) 2018-02-08
NZ630843A (en) 2017-01-27
HUE037966T2 (hu) 2018-09-28
CN104203279B (zh) 2018-10-30
JP6898960B2 (ja) 2021-07-07
LT2827900T (lt) 2018-05-10
PT3400943T (pt) 2021-02-02
CA2867723C (en) 2022-11-08
PL3400943T3 (pl) 2021-06-14
TR201808450T4 (tr) 2018-07-23
CN109223791A (zh) 2019-01-18
NZ756264A (en) 2022-09-30
EP2827900B1 (en) 2018-03-21
ES2855142T3 (es) 2021-09-23
EP3400943A1 (en) 2018-11-14
SG11201405954YA (en) 2014-10-30
US20230190749A1 (en) 2023-06-22
RU2018138976A3 (enExample) 2022-04-08
KR20200115656A (ko) 2020-10-07
EP3400943B1 (en) 2020-12-02
DK2827900T3 (en) 2018-05-07
US20150110780A1 (en) 2015-04-23
JP7404485B2 (ja) 2023-12-25
JP2024019526A (ja) 2024-02-09
EP4252855A2 (en) 2023-10-04
JP2017141302A (ja) 2017-08-17
ES2673165T3 (es) 2018-06-20
CY1120204T1 (el) 2018-12-12
SI3400943T1 (sl) 2021-03-31
AU2019203618B2 (en) 2021-08-05
NZ741615A (en) 2019-10-25
PH12014502032A1 (en) 2014-11-24
KR20210131426A (ko) 2021-11-02
KR102490961B1 (ko) 2023-01-19
RU2014142700A (ru) 2016-05-20
KR20140139009A (ko) 2014-12-04
UA122044C2 (uk) 2020-09-10
AU2013234921A1 (en) 2014-10-02
AU2019203618A1 (en) 2019-06-13
RU2018138976A (ru) 2018-12-06
WO2013142875A1 (en) 2013-09-26
IL269205B (en) 2020-06-30
HRP20180659T1 (hr) 2018-06-01
AU2017272232C1 (en) 2019-08-15
IL269205A (en) 2019-11-28
MY202114A (en) 2024-04-04
PH12021550360A1 (en) 2023-04-03
NZ724544A (en) 2018-05-25
HUE053156T2 (hu) 2021-06-28
PT2827900T (pt) 2018-06-14
JP2019081792A (ja) 2019-05-30
DK3400943T3 (da) 2021-02-08
MY174883A (en) 2020-05-20
SI2827900T1 (en) 2018-06-29
HK1206276A1 (en) 2016-01-08
AU2017272232A1 (en) 2018-01-04
CL2014002497A1 (es) 2014-11-14
KR102160462B1 (ko) 2020-09-28
CA2867723A1 (en) 2013-09-26
CY1123837T1 (el) 2022-05-27
RS57140B1 (sr) 2018-07-31
MX2014011437A (es) 2014-11-10
EP3842044A1 (en) 2021-06-30
IL261659A (en) 2018-10-31
RU2672575C2 (ru) 2018-11-16
AU2021261849A1 (en) 2021-12-02
SMT201800251T1 (it) 2018-07-17
CO7071139A2 (es) 2014-09-30
AU2017272232B2 (en) 2019-02-28
CN104203279A (zh) 2014-12-10
US11504370B2 (en) 2022-11-22

Similar Documents

Publication Publication Date Title
JP7404485B2 (ja) 脳癌の治療
HK40102024A (en) Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
HK40055793A (en) Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
HK40000406B (en) Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
HK40000406A (en) Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
HK1206276B (en) Amorphous solid dispersion for use in the treatment of brain cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170424

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170929